Recombinant adeno-associated viral (rAAV) vectors represent a novel class of biopharmaceutical drugs. The production of clinical-grade rAAV vectors for gene therapy would benefit from analytical methods that are able to monitor drug product quality with regard to homogeneity, purity, and manufacturing consistency. Here, we demonstrate the novel application of analytical ultracentrifugation (AUC) to characterize the homogeneity of preparations of rAAV vectors. We show that a single sedimentation velocity run of rAAV vectors detected and quantified a number of different viral species, such as vectors harboring an intact genome, lacking a vector genome (empty particles), and containing fragmented or incomplete vector genomes. This information is obtained by direct boundary modeling of the AUC data generated from refractometric or UV detection systems using the computer program SEDFIT. Using AUC, we show that multiple parameters contributed to vector quality, including the AAV genome form (i.e., self-complementary vs. single-stranded), vector genome size, and the production and purification methods. Hence, AUC is a critical tool for identifying optimal production and purification processes and for monitoring the physical attributes of rAAV vectors to ensure their quality.
Get full access to this article
View all access options for this article.
References
1.
HauswirthWW, AlemeanTS, KaushalS, et al.Treatment of Leber congenital amaurosis due to a RPE65 mutation by ocular subretinal injection of adeno-associated virus gene vector short-term results of a phase I trial. Hum Gene Ther, 2008; 19:979–990.
2.
BainbridgeJW, SmithAJ, BarkerSS, et al.Effect of gene therapy on visual frunction in Leber's congenital amaurosis. N Engl J Med, 2008; 358:2231–2239.
3.
CideciyanAV, AlemanT, BoyeSL, et al.Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow kinetics. Proc Natl Acad Sci USA, 2008; 105:15112–15117.
4.
CideciyanAV, HauswirthWW, AlemanTS, et al.Human RPE65 gene therapy for Leber congenital amaurosis—persistence of early visual improvements and safety at 1 year. Hum Gen Ther, 2009; 20:999–1004.
5.
CideciyanAV, HauswirthW, AlemanTS, et al.Vision 1 year after gene therapy for Leber's congenital amaurois. N Engl J Med, 2009; 361:725–727.
6.
MaguireAM, SimonelliF, PierceEA, et al.Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 2008; 398:2240–2248.
7.
MaguireAM, HighKA, AurricchioA, et al.Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase I dose-escalation trial. Lancet, 2009; 374:1597–1605.
8.
SimonelliF, MaguireAM, TestaF, et al.Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther, 2010; 18:643–650.
9.
NathwaniAC, TuddenhamEG, RangarajanS, et al.Adenovirus–associated virus vector mediated gene transfer in hemophilia B. N Engl J Med, 2011; 346:2357–2365.
10.
Yla-HerttualaS. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther, 2010; 20:1831–1832.
11.
AyusoE, MingozziF, BoschF. Production, purification and characterization of adeno- associated vectors. Curr Gene Ther, 2010; 10:423–436.
12.
BerkowitzSA, PhiloJ. Monitoring the homogeneity of adenovirus preparations (a gene therapy delivery system) using analytical ultracentrifugation. Anal Biochem, 2007; 362:16–37.
13.
YangX, AgarwalaS, RavindranS, et al.Determination of particle heterogeneity and stability of recombinant adenovirus by analytical ultracentrifugation in CsCl gradients. J Pharm Sci, 2006; 97:746–763.
14.
ZhaoH, BrautigamCA, GhirlandoR, SchuckP. Overview of current methods in sedimentation velocity and sedimentation equilibrium analytical ultracentrifugation. Curr Protoc Protein Sci, 2013; 20.12.1–20.12.49.
15.
SchuckP. Size Distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J, 2000; 78:1606–1619.
16.
PhiloJS. Analytical ultracentrifugation. In: Methods for Structural Analysis of Protein Pharmaceuticals. JiskootW, CrommelinD, eds. (AAPS, New York, NY). 2005; pp. 379–412.
17.
CalabrettaM, JamisonJA, FalknerJC, et al.Analytical ultracentrifugation for characterizing nanocrystals and their bioconjugates. Nano Lett, 2005; 5:963–967.
18.
ZhouCM, ZhangGX, MaXX. Characterization and evaluation of the immune responses elicited by a novel human papillomavirus (HPV) therapeutic vaccine: HPV16E7-HBcAg-Hsp65 fusion protein. J Virol Methods, 2014; 191–196.
19.
SrivastavaA, LusbyEW, BernsKI. Nucleotide seqeunce and organization of the adeno-assocaited virus 2 genome. J Virol, 1983; 45:555–564.
20.
SonntagF, SchmidtK, KleinschmidtJA. A viral assembly factor promotes AAV2 capsids formation in the nucleolus. Proc Natl Acad Sci USA, 2010; 107:10220–10225.
21.
GrimmD, KayMA, KleinschmidtJA. Helper virus-free optically controllable and two plasmid–based production of adeno–associated virus vectors of serotypes 1 to 6. Mol Ther, 2003; 7:839–850.
22.
MatsushitaT, ElligerS, ElligerC, et al.Adeno-associated virus vectors can be efficiently porduced without helper virus. Gene Ther, 1998; 5:938–945.
23.
XiaoX, LiJ, SamulskiRJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998; 72:2224–2232.
24.
KingJA, DubielzigR, GrimmD, etal.DNA helicase- mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J, 2001; 20:3282–3291.
25.
UrabeM, DingC, KotinRM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther, 2002; 13:1935–1943.
26.
UrabeM, NakakuraT, XinK, et al.Scalable generation of high titer recombinant adeno-associated virus type 5 in insect cells. J Virol, 2006; 80:1874–1885.
27.
SmithRH, LevvyJ, KotinRM. A simplified baculovirus AAV expression vector system coupled with one step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther, 2009; 17:1888–1896.
28.
ChenH. Intron splicing mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. Mol Ther, 2008; 16:924–930.
29.
HwangKK, MandellT, KintnerH, et al.High titer recombinant adeno-associated virus production using replication deficient herpes simplex virus type I. Mol Ther, 2003; 7:S14–S15.
30.
KangW, WangL, HarrellH, et al.An efficient rHSV–based complementation system for the production of multiple rAAV vector serotypes. Gene Ther, 2009; 16:229–239.
31.
ClarkKR, VoulgaropoulouF, FoletDM. et al.Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther, 1995; 6:1329–1341.
32.
GaoGP, QuG, FaustLZ, et al.High-titer adeno-associated viral vectors from a rep/cap cell line and hybrid shuttle virus. Hum Gene Ther, 1998; 9:2352–2362.
33.
ChadeufG, FavreD, TessierJ, et al.Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus induced amplification of the integrated rep-cap-genome. J Gene Med, 2000; 2:260–268.
34.
FarsonD, HardingTC, TaoL, et al.Development and characterization of a cell line for large scale, serum free production of recombinant adeno-associated viral vectors. J Gene Med, 2004; 6:1369–1381.
YuanZ, QiaoC, HuP, et al.A versatile adeno-associated virus vector producer cell line method for scaleable vector production of different serotypes. Hum Gene Ther, 2011; 22:613–624.
37.
MartinJ, FrederickA, LuoY, et al.Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. Hum Gene Ther Meth, 2013; 24:253–269.
38.
SatkunanathanS, WheelerJ, ThorpeR, et al.Establishment of a novel cell line for the enhanced production of recombinant adeno-associated virus vectors for gene therapy. Hum Gene Ther, 2014; 25:1–13.
39.
GaoK, LiM, ZhongL, et al.Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects. Mol Ther Meth Clin Dev, 2014; 1:9–13.
De La MazaLM, CarterBJ. Heavy and light particles of adeno associated virus. J Virol, 1980; 33:1129–1137.
42.
QuG, Bahr-DavidsonJ, PradoJ, et al.Separation of adeno-assocaited virus type 2 empty particles from genome containing vector by anion–exchange chromatography. J Virol Methods, 2007; 140:183–192.
43.
SommerJM, SmithPH, ParthasarathyS, et al.Quantification of adeno-assocaited virus particles and empty capsids by optical density measurement. Mol Ther, 2003; 7:122–128.
44.
HauckB, MurphySL, SmithPH, et al.Undetectable transcription of cap in a clinical AAV vector: Implications for preformed capsid in immune responses. Mol Ther, 2009; 17:144–152.
45.
ChadeufG, CironC, MoullierP, et al.Evidence for encapsidation of prokaryotic sequences during recombinant adeno-assocaited virus production and their in vivo persisitence after vector delivery. Mol Ther, 2005; 12:744–753.
46.
WuJW, ZhaoL, ZhangZ, et al.Self-complementary recombinant adeno-assocaited viral vectors: packaging capacity and the role of the rep proteins in vector purity. Hum Gene Ther, 2007; 18:171–182.
47.
ZeltnerN, KohlbrennerE, ClementN, et al.Near-perfect infectivity of wild type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther, 2010; 17:672–679.
48.
KapranovP, ChenL, DederichD, et al.Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther, 2012; 23:46–55.
49.
HorowitzED, RahmanKS, BowerBD, et al.Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. J Virol, 2013; 87:2994–3002.
50.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
